Citigroup analyst Carly Kenselaar upgrades Travere Therapeutics (NASDAQ:TVTX) from Neutral to Buy and raises the price target from $7 to $10.
Citigroup Upgrades Travere Therapeutics to Buy, Raises Price Target to $10
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.